697 related articles for article (PubMed ID: 23353012)
1. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
[TBL] [Abstract][Full Text] [Related]
2. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections.
Matinkhoo S; Lynch KH; Dennis JJ; Finlay WH; Vehring R
J Pharm Sci; 2011 Dec; 100(12):5197-205. PubMed ID: 22020816
[TBL] [Abstract][Full Text] [Related]
3. Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection.
Chang RY; Wong J; Mathai A; Morales S; Kutter E; Britton W; Li J; Chan HK
Eur J Pharm Biopharm; 2017 Dec; 121():1-13. PubMed ID: 28890220
[TBL] [Abstract][Full Text] [Related]
4. Effect of storage temperature on the stability of spray dried bacteriophage powders.
Leung SSY; Parumasivam T; Nguyen A; Gengenbach T; Carter EA; Carrigy NB; Wang H; Vehring R; Finlay WH; Morales S; Britton WJ; Kutter E; Chan HK
Eur J Pharm Biopharm; 2018 Jun; 127():213-222. PubMed ID: 29486303
[TBL] [Abstract][Full Text] [Related]
5. Instability of bacteriophages in spray-dried trehalose powders is caused by crystallization of the matrix.
Vandenheuvel D; Meeus J; Lavigne R; Van den Mooter G
Int J Pharm; 2014 Sep; 472(1-2):202-5. PubMed ID: 24950368
[TBL] [Abstract][Full Text] [Related]
6. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
7. Particle engineering of materials for oral inhalation by dry powder inhalers. I-Particles of sugar excipients (trehalose and raffinose) for protein delivery.
Ogáin ON; Li J; Tajber L; Corrigan OI; Healy AM
Int J Pharm; 2011 Feb; 405(1-2):23-35. PubMed ID: 21129458
[TBL] [Abstract][Full Text] [Related]
8. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
9. Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants.
Murugappan S; Patil HP; Kanojia G; ter Veer W; Meijerhof T; Frijlink HW; Huckriede A; Hinrichs WL
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):716-25. PubMed ID: 23933147
[TBL] [Abstract][Full Text] [Related]
10. Storage stability of inhalable phage powders containing lactose at ambient conditions.
Chang RYK; Wallin M; Kutter E; Morales S; Britton W; Li J; Chan HK
Int J Pharm; 2019 Apr; 560():11-18. PubMed ID: 30710661
[TBL] [Abstract][Full Text] [Related]
11. Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders.
Leung SSY; Parumasivam T; Gao FG; Carter EA; Carrigy NB; Vehring R; Finlay WH; Morales S; Britton WJ; Kutter E; Chan HK
Int J Pharm; 2017 Apr; 521(1-2):141-149. PubMed ID: 28163231
[TBL] [Abstract][Full Text] [Related]
12. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
[TBL] [Abstract][Full Text] [Related]
13. Bacteriophage Encapsulation Using Spray Drying for Phage Therapy.
Malik DJ
Curr Issues Mol Biol; 2021; 40():303-316. PubMed ID: 32678066
[TBL] [Abstract][Full Text] [Related]
14. A Design of Experiment Approach to Optimize Spray-Dried Powders Containing
Tabare E; Glonti T; Cochez C; Ngassam C; Pirnay JP; Amighi K; Goole J
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696356
[TBL] [Abstract][Full Text] [Related]
15. Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles.
Keil TWM; Feldmann DP; Costabile G; Zhong Q; da Rocha S; Merkel OM
Eur J Pharm Biopharm; 2019 Oct; 143():61-69. PubMed ID: 31445157
[TBL] [Abstract][Full Text] [Related]
16. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
17. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules.
Sou T; Kaminskas LM; Nguyen TH; Carlberg R; McIntosh MP; Morton DA
Eur J Pharm Biopharm; 2013 Feb; 83(2):234-43. PubMed ID: 23183447
[TBL] [Abstract][Full Text] [Related]
18. Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale.
Gikanga B; Turok R; Hui A; Bowen M; Stauch OB; Maa YF
PDA J Pharm Sci Technol; 2015; 69(1):59-73. PubMed ID: 25691715
[TBL] [Abstract][Full Text] [Related]
19. Phage cocktail powder for Pseudomonas aeruginosa respiratory infections.
Li M; Chang RYK; Lin Y; Morales S; Kutter E; Chan HK
Int J Pharm; 2021 Mar; 596():120200. PubMed ID: 33486032
[TBL] [Abstract][Full Text] [Related]
20. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
